Neddylation
| Neddylation | |||||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|||||||||
| Biochemical Reaction | |||||||||
| Part of | Cell | ||||||||
| Located | Nucleus, Cytoplasm | ||||||||
| Category | Post-translational modification | ||||||||
| Type | Protein-conjugating | ||||||||
| Central Functions | |||||||||
|
Regulation of Glucose & Lipid Metabolism
Immunoregulation & Modulation of Immune Cells
Regulation of Protein Degradation Pathways
Neurogenesis & Nervous System Development
|
|||||||||
| Key Enzymes | |||||||||
| Discovered | |||||||||
|
|||||||||
|
|
|||||||||
Protein neddylation refers to the post-translational modification in which ubiquitin-like protein NEDD8 is covalently attached to the lysine residue of a target protein, which is catalyzed by a cascade of enzymes including UBA3, NAE1, UBE2M or UBE2F, and NEDD8 E3 ligases. Neddylation belongs to the overall class of protein-conjugating post-translational modifications, which includes other reactions such as ubiquitination, SUMOylation, and ISGylation.
Neddylation has been reported for both histone and non-histone protein substrates, and thus represents a distinct epigenetic and proteomic regulatory mechanism with various implications in health and disease. Recent studies have unveiled the critical role of neddylation in mediating a wide range of physiological processes, in both the nervous system and beyond.
Neddylation is known to contribute to several significant diseases, including metabolic disorders, neurodegenerative diseases, and various cancers. To date, the best characterized protein substrates of neddylation belong to the cullin protein family (CUL), where neddylation is known to activate cullin RING ligases (CRLs).
Roles for protein neddylation have been reported for several neurological diseases, including ischemia, multiple sclerosis, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis, Alzheimer's disease, and hereditary spastic paraplegia. Overactive neddylation is known to influence both tumorigenesis and cancer metastasis, as well as therapeutic resistance (ie., to cancer treatment).